TOLREMO's co-founder and CEO, Dr. Stefanie Flückiger-Mangual, was featured on the Swisspreneur podcast discussing TOLREMO's approach to addressing non-genetic drug resistance, a universal problem for current and future targeted cancer therapies. In her episode of the Swisspreneur Show, Stefanie shares insights on navigating the biotech startup landscape and TOLREMO's ultimate goal of proving the efficacy of its treatment and joining forces with a larger pharma company.

Women in Stem with Stefanie Flückiger-Mangual

May, 2024

TOLREMO’s co-founder and CEO, Dr. Stefanie Flückiger-Mangual, was featured in a Women in Stem series as one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. Published by Drug Target Review, the article discusses her journey in leading the team of scientists who discovered novel molecular mechanisms that can be exploited to prevent the development of non-genetic resistance to cancer therapies.

ⓘ Click here for more information: Drug Target Review

TOLREMO RECEIVES CHF 1.5 MILLION FROM INNOSUISSE

December, 2023

TOLREMO secured a CHF 1.5 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation Project. The initiative supports start-ups prior to entering the market in the realisation of science-based innovation projects with significant potential. The grant is designed to expedite the market introduction of new products and services. TOLREMO has recently reached the clinic with its lead candidate, TT125-802, designed to prevent transcriptional cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.

ⓘ Click here for more information: Innosuisse

DR. STEFANIE FLÜCKIGER IS A FINALIST FOR THE 2024 SEF.WOMENAWARD

nOVEMBER, 2023

TOLREMO’s co-founder and CEO Dr. Stefanie Flückiger-Mangual was selected as a finalist for the 2024 SEF.WomenAward. Presented by NZZ Konferenzen & Services as part of the Swiss Economic Forum, the Young Entrepreneur of the Year award honors women with an inspirational history of achievement in entrepreneurship. The award ceremony will take place on March 8th at The Circle in Zurich.

ⓘ Click here for press coverage and more information: SEF Awards

DR. STEFANIE FLÜCKIGER IS NOMINATED AT THE EUROPEAN LIFESTARS AWARD

OCTOBER, 2023

TOLREMO’s co-founder and CEO Dr. Stefanie Flückiger-Mangual was nominated for the European Lifestars Award - Women-Led Business Leader of the Year. Organized by LSX, the network for life science executive leaders, the award celebrates the achievements of individuals, teams and organizations that have shaped he landscape of the life science industry in the past year.

ⓘ Click here for press coverage and more information: European Lifestars Award

Dr. Stefanie Flückiger is Innovator of the Year

July, 2022

TOLREMO’s co-founder and CEO, Dr. Stefanie Flückiger-Mangual, received the Innovator of the Year award at the Female Innovation Forum for her pioneering work with TOLREMO in combatting drug resistance in cancer. Sponsored by BMW, the award recognizes innovators whose contributions have the potential to significantly bolster the Swiss economy through groundbreaking ideas and solutions.

ⓘ Click here for press coverage and more information: Start-Up Ticker and Blick

Swiss Startup Award, TOLREMO

September, 2021

TOLREMO has once again secured a spot among Switzerland's elite startups. The Top 100 Startup Awards recognize and honor trailblazing companies dedicated to creating meaningful impact globally.

ⓘ Click here for press coverage and more information: Top 100 Swiss Startups